This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Paroxetine

Well Researched

SKIP-FOR-NOW for a 20yo MMA athlete + business owner — most potent SSRI but worst tolerability of the modern class (Cipriani 2018), severe withdrawal syndrome, prominent weight gain, anticholinergic burden, and pronounced sexual dysfunction make entry/exit cost incompatible with a healthy non-clinical user.

Aliases (5)

Paxil · Pexeva · paroxetine HCl · paroxetine mesylate · Brisdelle

TYPICAL DOSE

20-50 mg

Daily

ROUTE

Oral (tablet/CR/suspension)

CYCLE

Chronic; not cycled

STORAGE

Room temp; original container

Overview

What is Paroxetine?

Paroxetine (Paxil, Pexeva, Brisdelle) is a phenylpiperidine SSRI FDA-approved for MDD, OCD, panic disorder, GAD, PTSD, social anxiety disorder, and PMDD. Brisdelle 7.5 mg is the only non-hormonal Rx approved for moderate-to-severe menopausal hot flashes. Despite mid-tier efficacy in the Cipriani 2018 network meta-analysis, paroxetine has the worst acceptability profile of the common SSRIs and is widely considered among the most-discontinued antidepressants due to severe withdrawal syndrome.

Key Benefits

Highly potent serotonin reuptake inhibition with broad psychiatric indications. Brisdelle micro-dose effective for vasomotor symptoms in postmenopausal women without estrogen exposure. Once-daily dosing.

Mechanism of Action

Most potent SERT inhibitor of the SSRI class; in addition exerts mild muscarinic anticholinergic activity (highest of SSRIs), inhibition of neuronal nitric oxide synthase (contributing to pronounced sexual dysfunction via reduced NO-mediated genital vasodilation), and strong CYP2D6 inhibition (creating a large drug-interaction surface). Short ~21-hour half-life with no active metabolite means missed doses produce rapid plasma drops, underlying the most severe SSRI-discontinuation syndrome (brain zaps, dizziness, flu-like symptoms, paresthesias).

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Peptide Interactions

CBT / exposure therapy:

Synergistic

Combination outperforms either alone for OCD, panic, PTSD, SAD.

MAOIs (phenelzine, tranylcypromine, selegiline >10 mg, moclobemide, linezolid, methylene blue):

Avoid

Serotonin syndrome — fatal. 14-day washout each direction.

Tramadol, meperidine, MDMA, 5-HTP, St John's wort, triptans:

Avoid

additive serotonergic load.

Tamoxifen:

Avoid

CYP2D6 inhibition reduces conversion to active endoxifen → increased breast cancer mortality (Kelly 2010 BMJ population-level signal). Switch to escitalopram…

Pimozide, thioridazine:

Avoid

Contraindicated per label (CYP2D6 → QT/arrhythmia).

Codeine, hydrocodone, oxycodone, tramadol

Avoid

(when used for analgesia): CYP2D6 inhibition blunts conversion to active metabolites; analgesic efficacy reduced.

Atomoxetine, risperidone, aripiprazole, haloperidol, TCAs, metoprolol:

Avoid

CYP2D6 substrate accumulation.

NSAIDs, aspirin, warfarin:

Avoid

GI bleed/anticoagulant additive risk via SSRI platelet effect.

Anticholinergics (diphenhydramine, oxybutynin, TCAs):

Avoid

additive anticholinergic burden — paroxetine itself has the highest of the SSRI class.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

Generic vs branded

Generics are widely used and generally fine; brand differentiation matters mainly for CR (controlled-release) formulations where the matrix governs release rate.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety

Common (>10%): Sexual dysfunction (60-70%+ in head-to-head studies — highest of SSRIs), nausea (early), somnolence/sedation, sweating, dry mouth, constipation, dizziness, weight gain (long-term, often >5 kg over 1 year), fatigue.
Less common (1-10%): Tremor, bruxism, blurred vision, insomnia, anxiety/agitation, anorgasmia, urinary hesitancy, paresthesias.
Rare-serious (<1%): Serotonin syndrome (with MAOIs, tramadol, MDMA), hyponatremia (especially elderly), suicidal ideation <25 yo (FDA black box), QT prolongation at high doses (less than citalopram but additive), bleeding risk (platelet 5-HT depletion), angle-closure glaucoma (anticholinergic).
Pregnancy: FDA Category D — paroxetine carries a specific black box for first-trimester cardiac malformations (atrial/ventricular septal defects) above background. Largely avoided in women of childbearing age planning pregnancy.
Discontinuation syndrome: Most severe of any SSRI per Fava 2018 systematic review. Brain zaps, dizziness, flu-like symptoms, irritability, paresthesias, vivid dreams. Can persist weeks.